Polio Research Today is a free monthly online journal that collates and summarizes the latest research about Polio, including details on symptoms, treatment, vaccines, causes, virus.

Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.

Dragunsky EM, Ivanov AP, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM

Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. eugenia.dragunsky@fda.hhs.gov

Recently, we developed and optimized a new method for the evaluation of the protective properties of serotype 2 inactivated poliovirus vaccines (IPV). The method is based on the immunization and subsequent challenge of transgenic (Tg) mice susceptible to poliovirus. We describe a similar method for the assessment of the protectiveness of serotype 1 IPV and demonstrate that experimental IPV produced from attenuated Sabin strain (sIPV) of serotype 1 poliovirus induced serum neutralizing antibodies, immunoglobulin (Ig) G, IgM, and salivary IgA at titers comparable to those induced by conventional IPV (cIPV) produced from the wild-type Mahoney strain. In contrast to our previous results with serotype 2 sIPV, serotype 1 sIPV provided even better protection of Tg mice than cIPV against challenge with wild-type Mahoney strain.

Published 30 August 2006 in J Infect Dis, 194(6): 804-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Polio Research Today. All Rights Reserved.